Cambridge University and Medimmune announce oncology research collaboration | Research Capacity-Building in Africa |
The global biologics research and development arm of AstraZeneca will contribute both funding and a post-doctoral scientist to work within the laboratory of Professor Kevin Brindle at the University of Cambridge in the area of tumour targeted therapies (TTTs). TTTs encompass antibodies that are ‘armed’ to kill tumour cells, including antibody-drug conjugates (ADCs) that selectively aim powerful drugs at cancer cells.

Via Krishan Maggon